Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2012 | short review | Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012

Clinically useful biomarkers in neurooncology

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2012
Autor:
MD Matthias Preusser

Abstract

Many potential biomarkers have been proposed for brain tumors, but only few have been translated into actual clinical use yet. Here, the most commonly used biomarkers in adult neurooncology including 1p/19q codeletion status, O6-methylguanine-methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase (IDH) mutation status, and v-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E mutation status are briefly discussed with a focus on their clinical utility.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012Zur Ausgabe